GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (STU:3XV) » Definitions » Debt-to-Equity

Xvivo Perfusion AB (STU:3XV) Debt-to-Equity : 0.02 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Xvivo Perfusion AB Debt-to-Equity?

Xvivo Perfusion AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.97 Mil. Xvivo Perfusion AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €1.76 Mil. Xvivo Perfusion AB's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €177.01 Mil. Xvivo Perfusion AB's debt to equity for the quarter that ended in Mar. 2024 was 0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Xvivo Perfusion AB's Debt-to-Equity or its related term are showing as below:

STU:3XV' s Debt-to-Equity Range Over the Past 10 Years
Min: 0   Med: 0.02   Max: 0.2
Current: 0.02

During the past 12 years, the highest Debt-to-Equity Ratio of Xvivo Perfusion AB was 0.20. The lowest was 0.00. And the median was 0.02.

STU:3XV's Debt-to-Equity is ranked better than
92.28% of 712 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs STU:3XV: 0.02

Xvivo Perfusion AB Debt-to-Equity Historical Data

The historical data trend for Xvivo Perfusion AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB Debt-to-Equity Chart

Xvivo Perfusion AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 - 0.01 0.02

Xvivo Perfusion AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.02 0.01 0.02 0.02

Competitive Comparison of Xvivo Perfusion AB's Debt-to-Equity

For the Medical Devices subindustry, Xvivo Perfusion AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's Debt-to-Equity falls into.



Xvivo Perfusion AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Xvivo Perfusion AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Xvivo Perfusion AB's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xvivo Perfusion AB  (STU:3XV) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Xvivo Perfusion AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Xvivo Perfusion AB (STU:3XV) Business Description

Traded in Other Exchanges
Address
Massans gata 10, P.O. Box 53015, Gothenburg, SWE, SE-400 14
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.

Xvivo Perfusion AB (STU:3XV) Headlines

No Headlines